Global Montelukast API Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Application;

Asthma, Allergic Rhinitis , Bronchospasm , Urticaria, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn931883546 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Montelukast API Market (USD Million), 2021 - 2031

In the year 2024, the Global Montelukast API Market was valued at USD 1,478.84 million. The size of this market is expected to increase to USD 1,868.81 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.4%.

The Montelukast API market is anticipated to experience significant growth, characterized by an impressive Compound Annual Growth Rate (CAGR) from 2020 to 2030, driven by the rising demand for Montelukast API across a spectrum of respiratory and allergic conditions worldwide. Conditions such as asthma, allergic rhinitis, urticaria, bronchospasm, and others contribute to the increasing need for effective pharmaceutical interventions, with Montelukast API emerging as a vital component in managing these ailments. Its efficacy in addressing prevalent respiratory disorders like asthma and allergic rhinitis, coupled with its utility in managing conditions like urticaria and bronchospasm, underpins its broad market appeal. The accessibility of Montelukast API at the country level signifies its importance in healthcare systems globally, with insights into country-level opportunities providing valuable guidance for stakeholders seeking to capitalize on specific market dynamics. The projected exponential growth trajectory not only underscores the market's robust potential but also presents a conducive environment for investment, innovation, and strategic partnerships aimed at maximizing market share and profitability. In essence, the anticipated growth of the Montelukast API market reflects its pivotal role in addressing respiratory and allergic conditions on a global scale, driven by increasing demand, expanding applications, and lucrative opportunities across different countries.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Application
    2. Market Snapshot, By Region
  4. Global Montelukast API Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Asthma and Allergic Rhinitis
        2. Growing Awareness and Treatment-seeking Behavior
        3. Rising Healthcare Expenditure
        4. Advancements in Drug Delivery Technologies
        5. Expanding Geriatric Population
      2. Restraint
        1. Stringent Regulatory Requirements
        2. Generic Competition
        3. Side Effects and Safety Concerns
        4. Limited Treatment Options for Severe Cases
        5. Economic Instability
      3. Opportunities
        1. Expansion in Emerging Markets
        2. Development of Novel Formulations
        3. Strategic Collaborations and Partnerships
        4. Focus on Personalized Medicine
        5. Expansion of Indications
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market SegmentationCompetitive Landscape
    1. Global Montelukast API Market, By Application, 2021 - 2031 (USD Million)
      1. Asthma
      2. Allergic Rhinitis
      3. Bronchospasm
      4. Urticaria
      5. Others
    2. Global Montelukast API Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Merck Sharp & Dohme Corp
      2. Dr. Reddy’s Laboratories Ltd
      3. Morepen Laboratories Ltd
      4. Mylan N.V.
      5. Teva Pharmaceutical Industries Ltd
      6. Hikma Pharmaceuticals PLC
      7. Glenmark
      8. Sandoz International GmbH
      9. Vintage Pharmaceuticals Inc
      10. Hetero
      11. Aurobindo Pharma
  7. Analyst Views
  8. Future Outlook of the Market